Combination immunotherapy improves outcomes in NSCLC

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first-in-the-world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment.

May 08, 2026

Vol.52 No.18

Drugs & Targets

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA has accepted a New Drug Application for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act target action date is Feb. 27, 2027.

May 01, 2026

Vol.52 No.17

Drugs & Targets

Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

Nuvalent announced the submission of a New Drug Application to FDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive non-small cell lung cancer.

April 10, 2026

Vol.52 No.14

Funding Opportunities

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Combination immunotherapy improves outcomes in NSCLC

YOU MAY BE INTERESTED IN

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

FDA accepts NDA for zipalertinib for NSCLC with mutations

Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

SITC seeks applications for two fellowships

As more people are surviving cancer, we must continue funding bold science

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Renew today!

Subscriber content

Never miss an issue!

Login